Literature DB >> 22402856

Severe multiple sclerosis relapse under fingolimod therapy: incident or coincidence?

F Castrop1, M C Kowarik, H Albrecht, M Krause, B Haslinger, C Zimmer, A Berthele, B Hemmer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22402856     DOI： 10.1212/WNL.0b013e31824c46ad

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  7 in total

1.  Fingolimod after natalizumab and the risk of short-term relapse.

Authors:  Vilija G Jokubaitis; Vivien Li; Tomas Kalincik; Guillermo Izquierdo; Suzanne Hodgkinson; Raed Alroughani; Jeannette Lechner-Scott; Alessandra Lugaresi; Pierre Duquette; Marc Girard; Michael Barnett; Francois Grand'Maison; Maria Trojano; Mark Slee; Giorgio Giuliani; Cameron Shaw; Cavit Boz; Daniele L A Spitaleri; Freek Verheul; Jodi Haartsen; Danny Liew; Helmut Butzkueven
Journal:  Neurology       Date:  2014-03-07       Impact factor: 9.910

2.  New disease-modifying therapies and new challenges for MS.

Authors:  Vijayshree Yadav; Dennis Bourdette
Journal:  Curr Neurol Neurosci Rep       Date:  2012-10       Impact factor: 5.081

Review 3.  Bridging, switching or drug holidays - how to treat a patient who stops natalizumab?

Authors:  Joachim Havla; Ingo Kleiter; Tania Kümpfel
Journal:  Ther Clin Risk Manag       Date:  2013-10-03       Impact factor: 2.423

Review 4.  Neurological safety of fingolimod: An updated review.

Authors:  Fumihito Yoshii; Yusuke Moriya; Tomohide Ohnuki; Masafuchi Ryo; Wakoh Takahashi
Journal:  Clin Exp Neuroimmunol       Date:  2017-06-18

5.  Real-world use of fingolimod in patients with relapsing remitting multiple sclerosis: a retrospective study using the national multiple sclerosis registry in Kuwait.

Authors:  Jasem Al-Hashel; Samar F Ahmed; Raed Behbehani; Raed Alroughani
Journal:  CNS Drugs       Date:  2014-09       Impact factor: 6.497

Review 6.  Patient experience and practice trends in multiple sclerosis - clinical utility of fingolimod.

Authors:  Jong-Mi Lee; May H Han
Journal:  Patient Prefer Adherence       Date:  2015-05-21       Impact factor: 2.711

7.  A rare presentation of atypical demyelination: tumefactive multiple sclerosis causing Gerstmann's syndrome.

Authors:  Sharmilee Gnanapavan; Zane Jaunmuktane; Kelly Pegoretti Baruteau; Sakthivel Gnanasambandam; Klaus Schmierer
Journal:  BMC Neurol       Date:  2014-04-02       Impact factor: 2.474
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.